B. Riley Expects Reduced Earnings for Kymera Therapeutics

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Analysts at B. Riley reduced their Q3 2025 earnings estimates for shares of Kymera Therapeutics in a research report issued to clients and investors on Tuesday, June 3rd. B. Riley analyst K. Patel now expects that the company will post earnings per share of ($1.04) for the quarter, down from their prior estimate of ($1.00). B. Riley has a "Buy" rating and a $60.00 price objective on the stock. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics' Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($3.71) EPS, FY2026 earnings at ($4.03) EPS and FY2027 earnings at ($4.56) EPS.

A number of other brokerages have also issued reports on KYMR. Citigroup began coverage on shares of Kymera Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $52.00 price objective for the company. HC Wainwright increased their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. UBS Group cut their price objective on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Wall Street Zen raised shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, Guggenheim reaffirmed a "buy" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday. Two investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $59.82.

Kymera Therapeutics Trading Down 0.1%

NASDAQ KYMR traded down $0.04 on Friday, reaching $47.62. 986,878 shares of the stock were exchanged, compared to its average volume of 611,517. Kymera Therapeutics has a one year low of $19.45 and a one year high of $53.27. The company's 50-day simple moving average is $30.25 and its two-hundred day simple moving average is $35.78. The firm has a market capitalization of $3.10 billion, a PE ratio of -20.35 and a beta of 2.07.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $22.10 million for the quarter, compared to analysts' expectations of $11.38 million. During the same quarter last year, the business earned ($0.69) EPS. The firm's revenue was up 114.6% compared to the same quarter last year.

Institutional Trading of Kymera Therapeutics

Institutional investors have recently bought and sold shares of the stock. Blue Trust Inc. lifted its position in Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after buying an additional 270 shares during the last quarter. State of Wyoming bought a new stake in shares of Kymera Therapeutics during the fourth quarter worth $45,000. GF Fund Management CO. LTD. bought a new stake in shares of Kymera Therapeutics during the fourth quarter worth $55,000. KBC Group NV lifted its position in shares of Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after purchasing an additional 752 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Kymera Therapeutics during the first quarter worth $68,000.

Insider Buying and Selling

In related news, Director Elena Ridloff sold 12,000 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $46.10, for a total value of $553,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey W. Albers sold 6,349 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $311,101.00. The disclosure for this sale can be found here. Insiders sold a total of 48,349 shares of company stock worth $2,334,301 over the last three months. 16.01% of the stock is owned by insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.